Search results for "KRAS"
showing 10 items of 232 documents
Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a ra…
2009
Abstract Background This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma. Patients and methods For a maximum of six 29-day cycles, patients received cisplatin 100 mg/m2, day 1, plus 5-FU 1000 mg/m2, days 1–5 (CF), either alone or in combination with cetuximab (CET–CF; 400 mg/m2 initial dose followed by 250 mg/m2 weekly thereafter). The primary end point was tumor response. Tumor material was obtained for analysis of KRAS mutation status. Results Sixty-two eligible patients were included, 32 receiving CET–CF and 30 CF. Cetuximab did not exacerbate grade 3/4 toxicity, except for rash (6% ve…
Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)
2016
We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to20%), mPD (minor progression0 to20%) and PD (progression ≥20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8…
Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology
2016
Somatic mutation analysis represents a useful tool in selecting personalized therapy. The aim of our study was to determine the presence of common genetic events affecting actionable oncogenes using a MassARRAY technology in patients with advanced solid tumors who were potential candidates for target-based therapies. The analysis of 238 mutations across 19 oncogenes was performed in 197 formalin-fixed paraffin-embedded samples of different tumors using the OncoCarta Panel v1.0 (Sequenom Hamburg, Germany). Of the 197 specimens, 97 (49.2%) presented at least one mutation. Forty-nine different oncogenic mutations in 16 genes were detected. Mutations in KRAS and PIK3CA were detected in 40/97 (4…
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
2008
Abstract Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuximab- and panitumumab-based treatments in metastatic colorectal cancer (CRC) patients. Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases. Patients and Methods. We analyzed KRAS codon 12 and 13 mutations from formalin-fixed sections of 107 CRC primaries and related metastases. Eight pairs were excluded from the analysis because of the low amount of tumor tissue in the available samples. The main characteristics were: 50 men, 49 women; me…
RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial
2013
Background: RAS mutations predict resistance to anti-epidermal growthfactor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. We analysed RAS mutations in 30 non-metastatic rectal cancer patients treated with or without cetuximab within the 31 EXPERT-C trial. Methods: Ninety of 149 patients with tumours available for analysis were KRAS/BRAF wild-type, and randomly assigned to capecitabine plus oxaliplatin (CAPOX) followed by chemoradiotherapy, surgery and adjuvant CAPOX or the same regimen plus cetuximab (CAPOX-C). Of these, four had a mutation of NRAS exon 3, and 84 were retrospectively analysed for additional KRAS (exon 4) and NRAS (exons 2/4) mutations by using bi-di…
Final results from a randomized phase 3 study of FOLFIRI \pm$ panitumumab for second-line treatment of metastatic colorectal cancer
2013
Abstract: Background: The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. Patients and methods: Patients receiving one prior mCRC treatment were randomly assigned (1:1) to panitumumab (6.0 mg/kg)-FOLFIRI versus FOLFIRI every 2 weeks. Co-primary end points (PFS and OS) were prospectively analyzed by tumor KRAS status. Results: One thousand one hundred and eighty-six patient…
Bentisko biotopu identifikācija kā aizsargājamo jūras teritoriju kritēriju izveides sastāvdaļa
2017
Šī pētījuma mērķis bija analizēt informāciju par aizsargājamo jūras teritoriju izveidei nepieciešamo kritēriju kopumu un identificēt bentiskajiem biotopiem nepieciešamos kritērijus jaunu aizsargājamo teritoriju izveidei Baltijas jūras austrumu daļā, kā arī izveidot pilotteritoriju līdz šim nepētītajos ekskluzīvās ekonomikas zonas ūdeņos Baltijas jūras austrumu piekrastē,. Lauku darbi tika veikti 2016. gada 9. un 10. septembrī ekskluzīvās ekonomiskās zonas ūdeņos pie Latvijas-Lietuvas robežas, aptuveni 30 km attālumā no krasta, veicot zemūdens filmēšanu izvēlētajā zonā. Piloteritorijā dziļums variēja no 24 līdz 32 m un kopumā dominēja akmeņaini rifi ar 55% substrāta pārklājumu un mīdiju (Myt…
Palaeohistology helps reveal taxonomic variability in exceptionally large temnospondyl humeri from the Upper Triassic of Krasiejów, SW Poland
2023
For more than twenty years, palaeontological excavations have been carried out at the Upper Triassic site of Krasiejów (south-west Poland), providing thousands of skeletal elements belonging to various tetrapod groups. However, almost all bones are preserved in a disarticulated state. This generates problems in taxonomic assignment among closely related groups, e.g., stereospondyl amphibians. As far as cranial elements, the pectoral girdle bones and the intercentra are very diagnostic, while all other remaining skeletal elements are difficult to unambiguously assign between either the capitosaurid Cyclotosaurus intermedius or the trematosaurid Metoposaurus krasiejowensis, both originating f…
The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-l…
2012
TPS3637 Background: GA201 is a novel, dual-acting, humanized, glycoengineered IgG1 anti-EGFR monoclonal antibody, with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity in combination with signal inhibition. GA201 demonstrates significantly enhanced in vitro/vivo activity compared to cetuximab (cet) both as a single agent and in combination with irinotecan, in both KRAS mutant and BRAF mutant models and promising clinical activity in ph I and neo-adjuvant trials (Paz Ares et al, JCO 2011) including KRAS mutant mCRC. A randomized ph II program was launched: one study in NSCLC and GAIN-C in mCRC (NCT01326000), which is presented here. Methods: Main inclusion criteria are prog…
Latvijas piekrastes pašvaldību attīstības stratēģijas un to ietekme uz Baltijas jūras vides aizsardzību
2016
Šī pētījuma mērķis ir analizēt 17 piekrastes pašvaldību ( pilsētas: Jūrmala, Liepāja, Rīga, Ventspils un 13 novada pašvaldību : Carnikavas, Dundagas, Engures, Grobiņas, Limbažu, Mērsraga, Nīcas, Rojas, Rucavas, Salacgrīvas, Saulkrastu un Ventspils) attīstības stratēģijas, tā kā šīs pašvaldības var tiešā mērā ietekmēt piekrasti un jūru. Lai pārbaudītu izvirzīto hipotēzi – piekrastes pašvaldību attīstības stratēģijas ir fokusētas uz prioritātēm ,kurām ir potenciāls nodarīt kaitējumu Baltijas jūras videi – tika pielietotas kvalitatīvās, kvantitatīvās, aprakstošās un salīdzinošās metodes.Izstrādājot maģistra darbu, tika secināts, ka piekrastes pašvaldību attīstības stratēģijās vides jautājumi, …